We report the potential of the 2-gene signature composed by ANKRD6 and ITIH3, which predicts survival regardless of the tumor stage and the patients’ age, exhibiting HRs higher than those of the 5 genes individually, and whose score is higher in patients presenting recurrent disease. The gene discussed is ANKRD6; the disease is neoplasm.